FDA Approvals, News & Updates

A quick overview of new drugs and new indications related to oncology therapies approved by the FDA between January and April 8, 2018.
In 2017, the US Food and Drug Administration (FDA) approved 46 new drugs, a 21-year high.
The drugs included in this review were approved for the first time or received additional approvals by the US Food and Drug Administration in 2017 and are grouped here by several categories
As knowledge of lung cancer tumor cell biology has evolved, small-molecule drugs that target specific genetic mutations offer oncologists the opportunity to treat patients with NSCLC in a personalized fashion.
A recent addition to the treatment armamentarium for atopic dermatitis is the topical phosphodiesterase-4 inhibitor crisaborole (Eucrisa). In December 2016, the US Food and Drug Administration (FDA) approved crisaborole for the treatment of mild-to-moderate atopic dermatitis in patients aged ≥2 years.
Spasticity is a chronic condition that is characterized by an abnormal increase in tone or stiffness in ≥1 muscles that can interfere with movement and daily activities.
Approximately 22% of all non-Hodgkin lymphoma (NHL) cases are classified as follicular lymphoma, making it the second most common NHL subtype.
Short-term antibiotic therapy is the initial treatment of gastric MALT lymphoma and is effective in approximately 70% to 90% of patients. For relapsed gastric MALT lymphoma, nonsurgical treatment options include chemotherapy, bortezomib (Velcade), low-dose radiation, and rituximab (Rituxan).
Rheumatoid arthritis (RA), a chronic, inflammatory autoimmune disorder, affects approximately 1.5 million individuals in the United States; it is 3 times more common in women than in men.
Page 1 of 15
Results 1 - 10 of 149
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME